Uveal Melanoma

Curated

in context · predicts response to

GNAQ Mutationother → predicts response to Trametinib

sensitivity

Curated

in context · predicts response to

GNA11 Mutationother → predicts response to Cabozantinib

sensitivity

Curated

in context · predicts response to

GNAQ Q209 → predicts response to Refametinib

sensitivity

Curated

in context · predicts response to

GNA11 Mutationother → predicts response to Trametinib

sensitivity

Curated

in context · predicts response to

MET Overexpressionexpression → predicts response to Crizotinib

sensitivity

Curated

in context · predicts response to

GNA11 Mutationother → predicts response to JQ1

sensitivity

Curated

in context · predicts response to

GNAQ Mutationother → predicts response to JQ1

sensitivity

Curated

in context · predicts response to

MET Overexpressionexpression → predicts response to Selumetinib

resistance

Curated

in context · predicts response to

MET Overexpressionexpression → predicts response to Trametinib

resistance

Curated

in context · predicts response to

GNA11 Mutationother → predicts response to Mirdametinib

sensitivity

Curated

in context · predicts response to

GNA11 Mutationother → predicts response to Sotrastaurin Acetate

sensitivity

Curated

in context · predicts response to

BAP1 Mutationother → predicts response to Trichostatin A

sensitivity

Curated

in context · predicts response to

BAP1 Mutationother → predicts response to Vorinostat

sensitivity

Curated

in context · predicts response to

BAP1 Mutationother → predicts response to Panobinostat

sensitivity

Curated

in context · predicts response to

BAP1 Mutationother → predicts response to Valproic Acid

sensitivity

Curated

in context · predicts response to

GNAQ Mutationother → predicts response to Mirdametinib

sensitivity

Curated

in context · predicts response to

GNAQ Mutationother → predicts response to Sotrastaurin Acetate

sensitivity

Curated

in context · predicts response to

DDX43 Overexpressionexpression → predicts response to Selumetinib

resistance

Curated

in context · predicts response to

DDX43 Overexpressionexpression → predicts response to Mirdametinib

resistance

Curated

in context · predicts response to

DDX43 Overexpressionexpression → predicts response to Trametinib

resistance

Curated

Uveal Melanoma prognostic in …PROGNOSTIC_IN2 of 2
← prognostic in	BAP1 EXPRESSIONexpression	supports	B	Uveal Melanoma	1	Curated	civic	graph →
← prognostic in	EIF1AX MUTATIONother	supports	C	Uveal Melanoma	1	Curated	civic	graph →

Uveal Melanoma prognostic in …PROGNOSTIC_IN2 of 2

← prognostic in

BAP1 EXPRESSIONexpression

supports

Curated

← prognostic in

EIF1AX MUTATIONother

supports

Curated

Uveal Melanoma associated with …ASSOCIATED_WITH11 of 11
← associated with	GNAQ 2 source records aggregated	supports	B	Uveal Melanoma	2	Curated	civic	graph →
← associated with	GNA11	supports	B	Uveal Melanoma	1	Curated	civic	graph →
← associated with	BAP1	supports	B	Uveal Melanoma	1	Curated	civic	graph →
← associated with	GNAQ	supports	C	Uveal Melanoma	1	Curated	civic	graph →
← associated with	GNA11	supports	C	Uveal Melanoma	1	Curated	civic	graph →
← associated with	EIF1AX	supports	C	Uveal Melanoma	1	Curated	civic	graph →
← associated with	MET 2 source records aggregated	supports	D	Uveal Melanoma	2	Curated	civic	graph →
← associated with	GNA11 2 source records aggregated	supports	D	Uveal Melanoma	2	Curated	civic	graph →
← associated with	GNAQ 2 source records aggregated	supports	D	Uveal Melanoma	2	Curated	civic	graph →
← associated with	BAP1	supports	D	Uveal Melanoma	1	Curated	civic	graph →
← associated with	DDX43	supports	D	Uveal Melanoma	1	Curated	civic	graph →

Uveal Melanoma associated with …ASSOCIATED_WITH11 of 11

← associated with

GNAQ

2 source records aggregated

supports

Curated

← associated with

supports

Curated

← associated with

supports

Curated

← associated with

supports

Curated

← associated with

supports

Curated

← associated with

supports

Curated

← associated with

2 source records aggregated

supports

Curated

← associated with

2 source records aggregated

supports

Curated

← associated with

2 source records aggregated

supports

Curated

← associated with

supports

Curated

← associated with

supports

Curated

Uveal Melanoma investigated for …INVESTIGATED_FOR15 of 61show all (up to 200)
← investigated for	Cabozantinibsmall_molecule 2 source records aggregated	supports	B	Uveal Melanoma	2	Curated	civic	graph →
← investigated for	Trametinibsmall_molecule	supports	B	Uveal Melanoma	1	Curated	civic	graph →
← investigated for	Refametinibsmall_molecule	supports	C	Uveal Melanoma	1	Curated	civic	graph →
← investigated for	Trametinibsmall_molecule	supports	C	Uveal Melanoma	1	Curated	civic	graph →
← investigated for	Tebentafuspother	unknown	3	Uveal Melanoma	1	Curated	chembl	graph →
← investigated for	Selumetinibsmall_molecule	unknown	3	Uveal Melanoma	1	Curated	chembl	graph →
← investigated for	Melphalansmall_molecule	unknown	3	Uveal Melanoma	1	Curated	chembl	graph →
← investigated for	Dacarbazinesmall_molecule	unknown	3	Uveal Melanoma	1	Curated	chembl	graph →
← investigated for	Mirdametinibsmall_molecule 3 source records aggregated	supports	D	Uveal Melanoma	3	Curated	civic	graph →
← investigated for	JQ1small_molecule 2 source records aggregated	supports	D	Uveal Melanoma	2	Curated	civic	graph →
← investigated for	Selumetinibsmall_molecule 2 source records aggregated	supports	D	Uveal Melanoma	2	Curated	civic	graph →
← investigated for	Trametinibsmall_molecule 2 source records aggregated	supports	D	Uveal Melanoma	2	Curated	civic	graph →
← investigated for	Sotrastaurin Acetatesmall_molecule 2 source records aggregated	supports	D	Uveal Melanoma	2	Curated	civic	graph →
← investigated for	Crizotinibsmall_molecule	supports	D	Uveal Melanoma	1	Curated	civic	graph →
← investigated for	Trichostatin A	supports	D	Uveal Melanoma	1	Curated	civic	graph →

Uveal Melanoma investigated for …INVESTIGATED_FOR15 of 61show all (up to 200)

← investigated for

Cabozantinibsmall_molecule

2 source records aggregated

supports

Curated

← investigated for

Trametinibsmall_molecule

supports

Curated

← investigated for

Refametinibsmall_molecule

supports

Curated

← investigated for

Trametinibsmall_molecule

supports

Curated

← investigated for

Tebentafuspother

unknown

Curated

← investigated for

Selumetinibsmall_molecule

unknown

Curated

← investigated for

Melphalansmall_molecule

unknown

Curated

← investigated for

Dacarbazinesmall_molecule

unknown

Curated

← investigated for

Mirdametinibsmall_molecule

3 source records aggregated

supports

Curated

← investigated for

JQ1small_molecule

2 source records aggregated

supports

Curated

← investigated for

Selumetinibsmall_molecule

2 source records aggregated

supports

Curated

← investigated for

Trametinibsmall_molecule

2 source records aggregated

supports

Curated

← investigated for

Sotrastaurin Acetatesmall_molecule

2 source records aggregated

supports

Curated

← investigated for

Crizotinibsmall_molecule

supports

Curated

← investigated for

supports

Curated

Uveal Melanoma altered in cohorts of …ALTERED_INderived15 of 100show all (up to 200)
← altered in cohorts of	CCN4 62 / 80 cases (78 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	SLC45A4 61 / 80 cases (76 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	AARD 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	ADCY8 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	AGO2 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	ANXA13 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	ASAP1 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	ATAD2 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	C8orf76 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	CCN3 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	CHRAC1 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	COL14A1 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	COL22A1 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	COLEC10 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	CYRIB 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →

Uveal Melanoma altered in cohorts of …ALTERED_INderived15 of 100show all (up to 200)

← altered in cohorts of

CCN4

62 / 80 cases (78 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

SLC45A4

61 / 80 cases (76 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

AARD

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ADCY8

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

AGO2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ANXA13

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ASAP1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

ATAD2

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

C8orf76

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

CCN3

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

CHRAC1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

COL14A1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

COL22A1

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

COLEC10

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

← altered in cohorts of

CYRIB

60 / 80 cases (75 %) · ssm · TCGA-UVM

—

Observed

Uveal Melanoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 60show all (up to 200)
→ investigated in trials for	Ipilimumabmonoclonal antibody 23 trials (3 active) · roll-up of the cancer and its descendants	—	—	Uveal Melanoma	23	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 16 trials (3 active) · roll-up of the cancer and its descendants	—	—	Uveal Melanoma	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Tebentafuspother 10 trials (7 active) · roll-up of the cancer and its descendants	—	—	Uveal Melanoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Aldesleukinother 9 trials (3 active) · roll-up of the cancer and its descendants	—	—	Uveal Melanoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 9 trials (3 active) · roll-up of the cancer and its descendants	—	—	Uveal Melanoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Dacarbazinesmall_molecule 7 trials (1 active) · roll-up of the cancer and its descendants	—	—	Uveal Melanoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 6 trials (2 active) · roll-up of the cancer and its descendants	—	—	Uveal Melanoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Temozolomidesmall molecule 6 trials (0 active) · roll-up of the cancer and its descendants	—	—	Uveal Melanoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 5 trials (2 active) · roll-up of the cancer and its descendants	—	—	Uveal Melanoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Melphalansmall_molecule 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Uveal Melanoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Uveal Melanoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Crizotinibsmall_molecule 4 trials (3 active) · roll-up of the cancer and its descendants	—	—	Uveal Melanoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Lifileucelcell therapy 4 trials (3 active) · roll-up of the cancer and its descendants	—	—	Uveal Melanoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Sunitinibsmall molecule 4 trials (1 active) · roll-up of the cancer and its descendants	—	—	Uveal Melanoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Afliberceptother 3 trials (1 active) · roll-up of the cancer and its descendants	—	—	Uveal Melanoma	3	Observed	clinicaltrials	graph →

Uveal Melanoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 60show all (up to 200)

→ investigated in trials for

Ipilimumabmonoclonal antibody

23 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

16 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tebentafuspother

10 trials (7 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Aldesleukinother

9 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

9 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dacarbazinesmall_molecule

7 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

6 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Temozolomidesmall molecule

6 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fludarabinesmall molecule

5 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Melphalansmall_molecule

5 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

4 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Crizotinibsmall_molecule

4 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Lifileucelcell therapy

4 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sunitinibsmall molecule

4 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Afliberceptother

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

Uveal Melanoma studied in …STUDIED_INderived10 of 232show all (up to 200)
→ studied in	NCT05524935Phase 2 · active not recruiting Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma · condition mapped ONTOLOGY_EXACT · 232 trials mapped (69 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05607095Phase 1 · recruiting A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma · condition mapped ONTOLOGY_EXACT · 232 trials mapped (69 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07804186Phase 3 · recruiting Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma · condition mapped ONTOLOGY_EXACT · 232 trials mapped (69 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02678572Phase 3 · completed Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma · condition mapped ONTOLOGY_EXACT · 232 trials mapped (69 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05903937Phase 1 · not yet recruiting Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases · condition mapped ONTOLOGY_EXACT · 232 trials mapped (69 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06070012Phase 2 · recruiting Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma · condition mapped ONTOLOGY_EXACT · 232 trials mapped (69 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07183852Phase 1 · not yet recruiting Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma · condition mapped CURATED_BROADER · 232 trials mapped (69 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07803562Phase 2 · not yet recruiting Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp · condition mapped CURATED_BROADER · 232 trials mapped (69 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07076550Phase 1 · terminated A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma · condition mapped CURATED_BROADER · 232 trials mapped (69 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03025256Phase 1 · active not recruiting Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease · condition mapped CURATED_BROADER · 232 trials mapped (69 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →

Uveal Melanoma studied in …STUDIED_INderived10 of 232show all (up to 200)

→ studied in

NCT05524935Phase 2 · active not recruiting

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma · condition mapped ONTOLOGY_EXACT · 232 trials mapped (69 active)

—

Observed

→ studied in

NCT05607095Phase 1 · recruiting

A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma · condition mapped ONTOLOGY_EXACT · 232 trials mapped (69 active)

—

Observed

→ studied in

NCT07804186Phase 3 · recruiting

Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma · condition mapped ONTOLOGY_EXACT · 232 trials mapped (69 active)

—

Observed

→ studied in

NCT02678572Phase 3 · completed

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma · condition mapped ONTOLOGY_EXACT · 232 trials mapped (69 active)

—

Observed

→ studied in

NCT05903937Phase 1 · not yet recruiting

Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases · condition mapped ONTOLOGY_EXACT · 232 trials mapped (69 active)

—

Observed

→ studied in

NCT06070012Phase 2 · recruiting

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma · condition mapped ONTOLOGY_EXACT · 232 trials mapped (69 active)

—

Observed

→ studied in

NCT07183852Phase 1 · not yet recruiting

Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma · condition mapped CURATED_BROADER · 232 trials mapped (69 active)

—

Observed

→ studied in

NCT07803562Phase 2 · not yet recruiting

Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp · condition mapped CURATED_BROADER · 232 trials mapped (69 active)

—

Observed

→ studied in

NCT07076550Phase 1 · terminated

A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma · condition mapped CURATED_BROADER · 232 trials mapped (69 active)

—

Observed

→ studied in

NCT03025256Phase 1 · active not recruiting

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease · condition mapped CURATED_BROADER · 232 trials mapped (69 active)

—

Observed